McIlrath & Eck’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $658K | Sell |
1,870
-26
| -1% | -$9.27K | 0.05% | 121 |
|
|
2025
Q4 | $621K | Buy |
1,896
+1
| +0.1% | +$317 | 0.06% | 84 |
|
|
2025
Q3 | $535K | Sell |
1,895
-5
| -0.3% | -$1.45K | 0.06% | 82 |
|
|
2025
Q2 | $530K | Buy |
1,900
+847
| +80% | +$240K | 0.06% | 76 |
|
|
2025
Q1 | $328K | Buy |
1,053
+319
| +43% | +$94.2K | 0.04% | 100 |
|
|
2024
Q4 | $191K | Sell |
734
-353
| -32% | -$105K | 0.02% | 121 |
|
|
2024
Q3 | $350K | Buy |
1,087
+10
| +0.9% | +$3.27K | 0.05% | 94 |
|
|
2024
Q2 | $336K | Sell |
1,077
-21
| -2% | -$6.17K | 0.05% | 89 |
|
|
2024
Q1 | $312K | Buy |
1,098
+176
| +19% | +$51.5K | 0.05% | 90 |
|
|
2023
Q4 | $265K | Sell |
922
-73
| -7% | -$19.9K | 0.05% | 101 |
|
|
2023
Q3 | $267K | Sell |
995
-25
| -2% | -$6.24K | 0.05% | 100 |
|
|
2023
Q2 | $227K | Sell |
1,020
-54
| -5% | -$12.5K | 0.05% | 104 |
|
|
2023
Q1 | $260K | Buy |
1,074
+3
| +0.3% | +$736 | 0.06% | 90 |
|
|
2022
Q4 | $281K | Sell |
1,071
-110
| -9% | -$29.5K | 0.07% | 77 |
|
|
2022
Q3 | $266K | Buy |
1,181
+1
| +0.1% | +$242 | 0.07% | 76 |
|
|
2022
Q2 | $287K | Sell |
1,180
-12
| -1% | -$2.94K | 0.09% | 68 |
|
|
2022
Q1 | $288K | Buy |
1,192
+1
| +0.1% | +$230 | 0.08% | 67 |
|
|
2021
Q4 | $268K | Buy |
1,191
+40
| +3% | +$8.44K | 0.07% | 73 |
|
|
2021
Q3 | $245K | Sell |
1,151
-139
| -11% | -$32K | 0.07% | 71 |
|
|
2021
Q2 | $314K | Buy |
1,290
+234
| +22% | +$57.6K | 0.1% | 59 |
|
|
2021
Q1 | $263K | Buy |
1,056
+591
| +127% | +$141K | 0.09% | 58 |
|
|
2020
Q4 | $107K | Buy |
465
+14
| +3% | +$3.23K | 0.04% | 96 |
|
|
2020
Q3 | $115K | Hold |
451
| – | – | 0.05% | 74 |
|
|
2020
Q2 | $106K | Buy |
451
+41
| +10% | +$9.35K | 0.05% | 74 |
|
|
2020
Q1 | $83K | Hold |
410
| – | – | 0.05% | 76 |
|
|
2019
Q4 | $99K | Sell |
410
-185
| -31% | -$40.8K | 0.05% | 78 |
|
|
2019
Q3 | $115K | Sell |
595
-32
| -5% | -$6.14K | 0.06% | 64 |
|
|
2019
Q2 | $119K | Hold |
627
| – | – | 0.07% | 58 |
|
|
2019
Q1 | $119K | Sell |
627
-24
| -4% | -$4.58K | 0.07% | 58 |
|
|
2018
Q4 | $127K | Buy |
651
+36
| +6% | +$7.02K | 0.08% | 55 |
|
|
2018
Q3 | $128K | Buy |
615
+27
| +5% | +$5.32K | 0.07% | 60 |
|
|
2018
Q2 | $108K | Sell |
588
-65
| -10% | -$11.5K | 0.07% | 65 |
|
|
2018
Q1 | $111K | Sell |
653
-37
| -5% | -$6.79K | 0.07% | 75 |
|
|
2017
Q4 | $120K | Buy |
+690
| New | +$122K | 0.07% | 76 |
|
Other funds holding AMGN
McIlrath & Eck's AMGN Position: Q1 2026 in Review
McIlrath & Eck reduced its Amgen (AMGN) stake by 1.4% in Q1 2026, selling an estimated $9.27K and leaving 1,870 shares worth $658K. The position accounts for 0.05% of the portfolio, ranked #121.
McIlrath & Eck first reported a position in AMGN in Q4 2017 and has held it in 34 quarters since. 3,142 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.
- McIlrath & Eck held 1,870 shares of Amgen worth $658K as of Q1 2026.
- McIlrath & Eck sold 26 Amgen shares in Q1 2026, an estimated $9.27K.
- Amgen made up 0.05% of McIlrath & Eck's portfolio in Q1 2026, its #121 holding.
- McIlrath & Eck first reported a position in Amgen in Q4 2017 and has held it in 34 quarters since.
- 3,142 funds tracked by Wall St. Rank held Amgen as of Q1 2026.
Based on McIlrath & Eck's 13F filing for Q1 2026, filed 19 May 2026.